The immune signatures associated with superior BCG-primed HSP90-E6 booster vaccination provide important leads for further investigation of the direct role of IL-17 in protection against TB and a novel strategy to improve BCG-booster vaccines. This evidence concerns the gene IL17A and tuberculosis.